SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster.
Health Technology Insights: MHK Launches SmartProminence AI Solutions
This collaboration represents a forward-looking model for how CDMOs and CROs can collaborate to deliver synchronized solutions that help to de-risk programs, streamline planning, expedite study setup and optimize cost-efficiency across the entire development lifecycle. According to The American Society of Cell & Gene Therapy, there are more than 4,400 gene, cell and RNA therapies currently in development.
“By combining Fortrea’s global clinical reach with SCTbio’s manufacturing expertise in cell therapy, viral vectors and apheresis, we’re creating a framework for smarter protocol design, more resilient supply chains and faster, safer delivery of therapies to patients worldwide,” said Luděk Sojka, CEO of SCTbio. “We share the same vision: that early alignment between CDMO and CRO can transform complexity into opportunity.”
Health Technology Insights: Artera Secures $65Million Growth Investment and Reaches $100Million CARR
“Our collaboration with SCTbio represents a significant step forward in enhancing the cell and gene therapy ecosystem,” said Mark Morais, chief operating officer and president, Fortrea Clinical Development. “This collaboration is structured to empower customers with the right resources and relevant experience needed to accelerate their therapies from first-in-human trials to commercialization. This strategic collaboration enables us to address the most pressing challenges in the development of advanced therapies.”
The collaboration will harmonize clinical trial logistics with GMP manufacturing readiness, ensuring that cell and gene therapy programs benefit from synchronized planning and flawless execution. Together, the companies will work closely with clients to evaluate and optimize the pathway from early-stage development to first-in-human trials, later-stage clinical advancement and geographical expansions. By uniting Fortrea’s deep development experience from first-in-human studies to product approval, with SCTbio’s specialized manufacturing and release capabilities, the partnership aims to set a new benchmark for operational excellence in advanced therapy development.
Health Technology Insights: First Stop Health Joins ParetoHealth Network
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- GlobeNewswire
